Cetuximab, bevacizumab and panitumumab for the treatment of metastatic colorectal cancer after first-line chemotherapy

  • Technology appraisal guidance
  • TA242
  • Published: 
Download guidance (PDF)

5 Recommendations for further research

5.1

The Committee was aware that a phase 2 clinical trial (SPIRITT) comparing bevacizumab plus FOLFIRI with panitumumab plus FOLFIRI after first-line treatment is under way. The expected study completion date is August 2012. The Committee noted that the results of this trial should be considered in any future review decision for this appraisal.